Forbes July 3, 2024
Robert Hart

Topline

British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker’s vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.

Key Facts

What Happened To Curevac And What Will It Do Now?

mRNA specialist CureVac started working with GSK to develop shots using the technology during the early stages of the COVID-19 pandemic. The pair fell behind other companies like Moderna, Pfizer and BioNTech, who rapidly brought shots to market, and the duo has failed to develop shots of comparable efficacy in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Healthcare System, Mergers & Acquisitions / JV, Pharma / Biotech, Public Health / COVID, Trends
Related Articles:
How Americans feel about weight-loss drugs, in 3 charts
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report

Share This Article